- Home
- CTVA vs TAK Comparison
CTVA vs TAK Comparison
Compare CTVA & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTVA | TAK |
|---|---|---|
| Founded | 1802 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7B | 43.3B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTVA | TAK |
|---|---|---|
| Price | $76.31 | $18.66 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $80.13 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 3.1M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | 0.93% | ★ 2.83% |
| EPS Growth | ★ 23.08 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $17,401,000,000.00 | N/A |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | $3.09 | $0.95 |
| P/E Ratio | $48.13 | ★ $41.25 |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $53.40 | $12.99 |
| 52 Week High | $77.41 | $18.79 |
Technical Indicators
Market Signals| Indicator | CTVA | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 76.26 |
| Support Level | $73.87 | $18.20 |
| Resistance Level | $77.11 | $18.79 |
| Average True Range (ATR) | 1.59 | 0.21 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 85.52 | 88.72 |
Price Performance
Historical ComparisonAbout CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in 2026 and will become a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.